Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation

EMBO Journal

Volumn 21, Issue 7, 2002, Pages 1628-1637

  Petäjä Repo, Ulla E ^a   Hogue, Mireille ^a   Bhalla, Suparna ^a   Laperrière, André ^a   Morello, Jean Pierre ^a   Bouvier, Michel ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Endoplasmic reticulum; G protein coupled receptor; Opioids; Pharmacological chaperone

Indexed keywords

CHAPERONE; DELTA OPIATE RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; MEMBRANE PROTEIN; PROTEASOME;

ARTICLE; CELL SURFACE; CONFORMATION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; HYDROPHOBICITY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

BREFELDIN A; CELL LINE; ENDOPLASMIC RETICULUM; ENKEPHALIN, LEUCINE; HUMANS; LIGANDS; MOLECULAR CHAPERONES; NALTREXONE; NARCOTIC ANTAGONISTS; PROTEIN PRECURSORS; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, OPIOID, DELTA;

EID: 0037007201     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/21.7.1628     Document Type: Article

References (43)

1. The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H2 receptor
2. Integration of endoplasmic reticulum signaling in health and disease
3. Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein
4. Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist
5. Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein
6. Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency
7. High-efficiency transformation of mammalian cells by plasmid DNA
8. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site
9. Setting the standards: Quality control in the secretory pathway
10. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor
11. 125I]ARM100613, a high-affinity radioligand for δ opioid receptors
12. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors
13. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility
14. Proper folding and endoplasmic reticulum to Golgi transport of tyrosinase are induced by substrates, DOPA and tyrosinase
15. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa
16. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: Disorders of protein trafficking and the role of ER molecular chaperones
17. Biosynthesis and degradation of CFTR
18. 1B-adrenoceptor by ligands that act as inverse agonists
19. Effect of vitamin A supplementation on rhodopsin mutants threonine-17→methionine and proline-347→serine in transgenic mice and in cell cultures
20. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: Evidence for membrane cycling from Golgi to ER
21. Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators
22. Nephrogenic diabetes insipidus
23. Pharmacological chaperones rescue cellsurface expression and function of misfolded V2 vasopressin receptor mutants
24. Pharmacological chaperones: A new twist on receptor folding
25. Crystal structure of rhodopsin: A G protein-coupled receptor
26. Export from the endoplasmic resticulum represents the limiting step in the maturation and cell surface expression of the human δ opioid receptor
27. Newly synthesized human 5 opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated and degraded by the proteasome
28. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constrains
29. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance and reward in rats
30. The δ-opioid receptor: Molecular pharmacology, signal transduction and the determination of drug efficacy
31. Opioid analgesics and antagonists
32. 2adrenergic receptor: Pharmacological creation of a phenotype in transgenic mice
33. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation
34. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
35. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice
36. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones
37. Mutations of gonadotropins and gonadotropin receptors: Elucidating the physiology and pathophysiology of pituitary-gonadal function
38. Involvement of Trp-284, Val-296 and Val-297 of the human δ-opioid receptor in binding of δ-selective ligands
39. 6-Aminohexanoic acid as a chemical chaperone for apolipoprotein(a)
40. 2A-adrenergic receptor
41. 2aadrenergic receptor conformational stability and cell-surface turnover
42. Opiate receptor changes after chronic exposure to agonists and antagonists
43. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects